API | emapalumab-lzsg

emapalumab-lzsg (gamifant) Report issue

Biologics mAb Orphan Drug ^FDA Approved ^FDA Priority Review ^FDA

AACT Drugs@FDA

Active Ingredient History

NOW

Emapalumab, sold under the brand name Gamifant, is an anti-interferon-gamma (IFNγ) antibody medication used for the treatment of hemophagocytic lymphohistiocytosis (HLH), which has no cure. ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecules: Missing data

More Chemistry

Pharmacology

Mechanisms of Action:
Multi-specific: No
Black Box: Missing data
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: Missing data

Drug Pricing (per unit)

United States

$5187.4600 - $16630.5000

More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

emapalumab-lzsg | ni-0501

Organizations (17)

Research & Development (17)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (1)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (9)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (9)

Allografts (Phase 2)

Arthritis, Juvenile (Phase 2)

Healthy Volunteers (Phase 1)

Lupus Erythematosus, Systemic (Phase 3)

Lymphohistiocytosis, Hemophagocytic (Phase 3)

Macrophage Activation Syndrome (Phase 3)

Rare Diseases (Phase 1)

SARS-CoV-2 (Phase 2/Phase 3)

Still's Disease, Adult-Onset (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 10
# of Trial Organizations: 17

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue